Imaging end points for monitoring neuroprotection in Parkinson's disease

Brooks, David J.

doi:10.1002/ana.10480

Cited by 48 publications

(21 citation statements)

References 63 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 12-month-old mice, however, the more severely affected lateral striatum showed less recovery in both genotypes. Functionally, the lateral striatum, which receives input from the sensorimotor cortex and lateral substantia nigra, is more highly correlated with most aspects of motor function (Gerfen, 1984;McGeorge and Faull, 1989;Voorn et al, 2004) and dysfunction in Parkinson's disease (PD) (Brooks, 2003) than is the medial striatum.…”

Section: Gdnfmentioning

confidence: 99%

Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice

Boger¹,

Middaugh²,

Patrick³

et al. 2007

J. Neurosci.

View full text Add to dashboard Cite

Methamphetamine abuse in young adults has long-term deleterious effects on brain function that are associated with damage to monoaminergic neurons. Administration of glial cell line-derived neurotrophic factor (GDNF) protects dopamine neurons from the toxic effects of methamphetamine in animal models. Therefore, we hypothesized that a partial GDNF gene deletion would increase the susceptibility of mice to methamphetamine neurotoxicity during young adulthood and possibly increase age-related deterioration of behavior and dopamine function. Two weeks after a methamphetamine binge (4 ϫ 10 mg/kg, i.p., at 2 h intervals), GDNF ϩ/Ϫ mice had a significantly greater reduction of tyrosine hydroxylase immunoreactivity in the medial striatum, a proportionally greater depletion of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the striatum, and a greater increase in activated microglia in the substantia nigra than wild-type mice. At 12 months of age, methamphetamine-treated GDNF ϩ/Ϫ mice exhibited less motor activity and lower levels of tyrosine hydroxylase-immunoreactivity, dopamine, DOPAC, and serotonin than wild-type mice. Greater striatal dopamine transporter activity in GDNF ϩ/Ϫ mice may underlie their differential response to methamphetamine. These data suggest the possibility that methamphetamine use in young adults, when combined with lower levels of GDNF throughout life, may precipitate the appearance of parkinsonian-like behaviors during aging.

show abstract

Section: Gdnfmentioning

confidence: 99%

Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice

Boger¹,

Middaugh²,

Patrick³

et al. 2007

J. Neurosci.

View full text Add to dashboard Cite

show abstract

“…FDOPA PET and ␤-CIT SPECT show a 4% to 13% yearly reduction in baseline putamen uptake compared with 0 -2.5% in healthy controls in longitudinal studies. 6,7 This technique has also been used to estimate the duration of the preclinical period of PD using a linear regression analysis. 16 Striatal FDOPA measurements correlate with dopamine cell counts measured in postmortem specimens 17,18 and striatal DAT binding decreases with age in healthy volunteers and PD patients.…”

Section: Dopaminergic Imaging In Parkinson S Disease: Neuroprotectionmentioning

confidence: 99%

“…3,4 Brain imaging in movement disorders was originally introduced to visualize the pathological changes associated with different clinical syndromes. 5 Subsequently, these techniques have been used in longitudinal studies designed to assess disease progression 6,7 and the effects of potential neuroprotective strategies. 8 -10 Lately, functional imaging has also been applied in the objective assessment of symptomatic treatment responses.…”

Section: Introductionmentioning

confidence: 99%

Neuroimaging and therapeutics in movement disorders

Eckert

Eidelberg

2005

Neurotherapeutics

View full text Add to dashboard Cite

Summary:In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson's disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.

show abstract

“…Beyin FDG PET görüntüleme bulgularına dayanan tanısal sınıflandırma kesin klinik tanı ile %90 oranında örtüşmekte ve nörodejeneratif parkinsonizm nedenleri (PH, MSA, PSP ve LCD) %90 oranında ayırt edilebilmektedir (21,22,35,40). Parkinsonizm sendromlarında beyin FDG PET görüntüleme saptanan anormal bulguların yaygınlığı ve derecesi klinik bulgular ile genellikle korelasyon gösterir (1,3,19,23,24,30,34,35,39,49,50,51,52). PH için klinik belirtiler ile ilişkili özgül metabolik tutulum biçimleri bulunur: Örneğin; tremor ile ilişkili serebellotalamo-kortikal yolakların etkilendiği (23,31,53); motor belirtiler ile ilişkili olarak putamen ve premotor korteksi içine alan (19,50,52,53); bilişsel bozukluklar ile ilişkili olarak da frontal ve parietal asosiyasyon alanlarında hipometabolizma ve serebellumda hipermetabolizma ile karakterize özgül metabolik ağ yapıları tanımlanmıştır (53,54).…”

Section: Beyin Fluorodeoksiglukoz Pozitron Emisyon Tomografisibulgularıunclassified

Nuclear Medicine Applications in Movement Disorders

Akdemir¹,

Atay²

2017

Nts

View full text Add to dashboard Cite

Öz Abstract GirişNükleer tıp görüntülemenin ilgi alanında beyindeki nörodejeneratif patolojik süreçlere bağlı olarak gelişen hipokinetik hareket bozukluğu hastalıkları yer alır. Parkinson hastalığının (PH) hipokinetik hareket bozukluğunun en sık görülen nedeni olması ve bu grupta bulunan diğer hastalıkların PH ile benzer klinik bulgular göstermesi nedeniyle bu hastalıklarda ortaya çıkan klinik tablo parkinsonizm olarak adlandırılır. Parkinsonizmde temel klinik bulgular tremor, rijidite, bradikinezi ve postürel dengesizliktir. Bu bulgular PH dışında Parkinson artı (Parkinson plus) sendromları olarak adlandırılan multi-sistem atrofi (MSA), progresif supra-nükleer palsi (PSP), kortikobazal dejenerasyon (KBD) ve Lewy-cisimcikli demansta da (LCD) görülür (1). Özellikle hastalığın erken döneminde nörodejeneratif özellikteki bu Parkinson artı sendromları klinik olarak PH ile karışabilir (2). Bunların dışında dopaminerjik nöron kaybına neden olmayan esansiyel tremor (ET) ve diğer sekonder parkinsonizm nedenlerinin (ilaç kullanımına, serebrovasküler olaya, travmaya veya enfeksiyona Ya zış maAd re si/Ad dressforCor res pon den ce

show abstract

Imaging end points for monitoring neuroprotection in Parkinson's disease

Cited by 48 publications

References 63 publications

Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice

Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice

Neuroimaging and therapeutics in movement disorders

Nuclear Medicine Applications in Movement Disorders

Contact Info

Product

Resources

About